GSK and Dr Reddy's sign agreement for US oral penicillin facility

GSK will transfer ownership of its penicillin manufacturing site in Tennessee

GlaxoSmithKline and Dr Reddy's Laboratories have signed an agreement relating to GSK's US oral penicillin facility and product portfolio.

As per the terms of the agreement, GSK will transfer ownership of its penicillin manufacturing site in Bristol, Tennessee, US, and rights for the Augmentin and Amoxil brands in the US to Dr Reddy's while it will retain the existing rights for these brands outside the US.

Antibiotics and Emerging Markets Supply senior vice president Jean-Paul Reynaud said that the sale of this site and divestiture of these products in the US is a positive step forward for the manufacturing facility.

Dr Reddy's Laboratories Global Generics Business president and head Abhijit Mukherjee said that they were excited about this acquisition, as it allows them to enter the US penicillin-containing antibacterial market segment and serve the needs of their customers and patients through manufacturing capabilities that did not previously exist within Dr Reddy's.